Literature DB >> 23258240

[Predictors of liver fibrosis in patients with non-alcoholic fatty liver disease. The role of metabolic syndrome, insulin-resistance and inflammation].

Paola Andreozzi1, Giovanni Viscogliosi, Franco Colella, Miroslava Subic, Elisa Cipriani, Benedetta Marigliano, Walter Verrusio, Adriana Servello, Evaristo Ettorre, Vincenzo Marigliano.   

Abstract

INTRODUCTION: NAFLD (non-alcoholic fatty liver disease) reaches an high prevalence in the general population, and it is closely related to metabolic syndrome (MetS). The entity of metabolic abnormalities and the chronic inflammation seem to play a main role in the development of liver fibrosis. The aim of our study is to determine whether subjects with NAFLD and MetS have higher liver fibrosis degree when compared with NAFLD subjects without MetS, and to investigate the relations between fibrosis, MetS and its single components and inflammation.
MATERIALS AND METHODS: We considered 24 patients with NAFLD. Those who had viral- and alcohol- related liver disease were excluded. MetS was diagnosed according to NCEP ATP III criteria; inflammatory status was determined through C-reactive protein (PCR) assay. The peripheral insulin-resistance was assessed by calculating HOMA ir. Liver fibrosis was measured by transient elastography (Fibroscan®).
RESULTS: Subjects with MetS had higher HOMA ir, PCR and Fibroscan® score (log value: 0.92±0.24 KPa vs 0.73±0.2 KPa; p=0.047). The linear correlation analysis showed that Fibroscan® score was related to MetS, number of MetS components, waist circumference, HOMA ir and PCR. However the multivariate regression analysis showed that only HOMA ir (B=0.077; 95%CI: -0.002- 0.157; p=0.05) and PCR (B=0.152; 95% CI: 0.006 - 0.299; p=0.006) were independent predictors of higher Fibroscan® score.
CONCLUSION: MetS is associated to higher liver fibrosis degree in subjects with NAFLD. The insulin-resistance and inflammation seem to be the main determinants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23258240     DOI: 10.1701/1206.13358

Source DB:  PubMed          Journal:  Recenti Prog Med        ISSN: 0034-1193


  5 in total

1.  Combined detection of liver stiffness and C-reactive protein in patients with hepatitis B virus-related liver cirrhosis, with and without hepatocellular carcinoma.

Authors:  Xiao-Yan Liu; Li-Na Ma; Ting-Ting Yan; Zhen-Hui Lu; Yuan-Yuan Tang; Xia Luo; Xiang-Chun Ding
Journal:  Mol Clin Oncol       Date:  2016-01-26

2.  Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.

Authors:  Li-Na Ma; Xiao-Yan Liu; Zhen-Hui Lu; Li-Gang Wu; Yuan-Yuan Tang; Xia Luo; Yan-Chao Hu; Ting-Ting Yan; Qi Wang; Xiang-Chun Ding; Yan Xie
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

3.  Serum C-reactive protein predicts early mortality in hospitalized patients with HBV-related decompensated cirrhosis.

Authors:  ShaoMing Zhu; Yulituzi Waili; XiaoTing Qi; YueMei Chen; YuFeng Lou; Bo Chen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 4.  Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases.

Authors:  JianPing Wu; WeiLin Mao
Journal:  Dis Markers       Date:  2020-07-21       Impact factor: 3.434

5.  Misdiagnosing hepatic inflammatory pseudotumor as hepatocellular carcinoma: A case report.

Authors:  Lei Yin; Bin Zhu; Xin-Yuan Lu; Wan Yee Lau; Yong Jie Zhang
Journal:  JGH Open       Date:  2017-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.